British research charity Wellcome and The Bill and Melinda Gates Foundation are each to contribute $50 million to a new fund to fight COVID-19.
With an additional $25 million donation from the Mastercard Impact Fund, a new COVID-19 Therapeutics Accelerator will be established to coordinate research efforts and remove obstacles to drug development.
The project will seek to accelerate the development of both new and repurposed drugs and biologics for immediate treatment of people infected with the coronavirus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze